Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

SFJ Pharmaceuticals® partner, Apellis, enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications outside the U.S.

Wednesday, October 28, 2020

SFJ Pharmaceuticals® ("SFJ") is pleased to note that its partner Apellis Pharmaceuticals Inc. ("Apellis") (Waltham, MA) and Swedish Orphan Biovitrum AB announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases including paroxysmal nocturnal hemoglobinuria (PNH). 

Under the terms of the agreement, Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for pegcetacoplan, including for hematologic indications. The strategic partnership allows Apellis to leverage Sobi's commercial capabilities and leadership in hematology and rare diseases to drive potential first regulatory approval in PNH and accelerate its internationalization.

A link to the announcement by Apellis can be found at https://investors.apellis.com/news-releases.

SFJ entered a novel risk-sharing collaboration with Apellis to develop pegcetacoplan in hematologic indications in February 2019.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024